Peptide gold rush: US policy shift exposes safety and regulatory gaps
Public comments on a US Department of Health and Human Services (HHS) policy allowing pharmacies to compound six injectable peptides close today. Some of the compounds have built an online following for promised beauty benefits, such as skin rejuvenation and hair growth.Under a draft interim policy, issued in late October, HHS says it will not take enforcement action against licensed pharmacies, physicians, and federal facilities that compound the six peptides — provided they meet conditions covering ingredient sourcing, testing, and adverse event reporting.This Technical Paper is brought to you by Ashland.
At SupplySide Global 2026, Lubrizol highlighted its latest ingredients and technology capabilities targeting the beauty-from-within space. Personal Care Insights speaks with Stephen Glass, account manager at Lubrizol, who discusses the trends shaping nutraceutical innovation today. The company also addresses the growing body of scientific evidence behind its ingredient Curcushine and its potential skin benefits for women across different life stages.
Settings
- Play Interval
- Slide Duration
- Thumbnail Bar Position
Latest headlines

The new era of beauty from within Nov 2026

Healthy aging heroesNov 2026
Multimedia
At SupplySide Global 2026, Lubrizol highlighted its latest ingredients and technology capabilities targeting the beauty-from-within space. Personal Care Insights speaks with Stephen Glass, account manager at Lubrizol, who discusses the trends shaping nutraceutical...






























